Climb Bio Inc
NGM: CLYMLive Quote
About Climb Bio Inc
Healthcare
Biotechnology
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
📊 Fundamental Analysis
Climb Bio Inc demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -32.1%, which indicates that capital utilization is currently under pressure.
At a current price of $8.41, CLYM currently trades near the top of its 52-week range (99%) (Range: $1.13 - $8.52).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$637.60M
Trailing P/E
--
Forward P/E
-5.76
Beta (5Y)
-0.20
52W High
$8.52
52W Low
$1.13
Avg Volume
579K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App